Phase I Study of Selinexor, Ixazomib, and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Clin Lymphoma Myeloma Leuk. 2020 Mar;20(3):198-200. doi: 10.1016/j.clml.2019.12.013. Epub 2019 Dec 26.
No abstract available

Publication types

  • Clinical Trial, Phase I
  • Letter
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / pharmacology
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Boron Compounds / pharmacology
  • Boron Compounds / therapeutic use*
  • Dexamethasone / pharmacology
  • Dexamethasone / therapeutic use*
  • Female
  • Glycine / analogs & derivatives*
  • Glycine / pharmacology
  • Glycine / therapeutic use
  • Humans
  • Hydrazines / pharmacology
  • Hydrazines / therapeutic use*
  • Male
  • Middle Aged
  • Multiple Myeloma / drug therapy
  • Neoplasm Recurrence, Local
  • Triazoles / pharmacology
  • Triazoles / therapeutic use*

Substances

  • Boron Compounds
  • Hydrazines
  • Triazoles
  • selinexor
  • ixazomib
  • Dexamethasone
  • Glycine